close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

46.25 +0.31 (+0.67%)
Official Closing Price Updated: 4:10 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
82 83 Next >
News headline image
3 Blue Chip Dividend Stocks To Play Defense ↗
We will discuss 3 long-term blue chip stocks to play defense. They have raised their dividends each year for over ten years, have current yields above the S&P 500 Index average, and should continue to... 
Via Talk Markets
Topics Stocks
News headline image
Bristol Myers Squibb (BMY) Q4 2023 Earnings Call Transcript ↗
BMY earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations ↗
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system. 
Via Benzinga
Topics Economy
News headline image
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review ↗
The Dow led the major indexes higher. Big techs diverged on results. 
Via Investor's Business Daily
Topics Economy Stocks
News headline image
Bristol-Myers Squibb's Earnings Outlook ↗
 
Via Benzinga
News headline image
Is Bristol Myers Squibb Stock a Buy Now? ↗
This healthcare stock has seen healthier days. 
Via The Motley Fool
News headline image
What's Going On With US Pharma Giant Bristol-Myers Squibb Stock Today? ↗
Bristol Myers Squibb reports Q4 revenues of $11.48 billion, up 1% YoY. Eliquis and Opdivo sales drive growth, offsetting Revlimid decline. 
Via Benzinga
News headline image
Bristol Myers Shares Rise On Fourth-Quarter Earnings Beat ↗
Bristol Myers earnings came in above expectations, although Opdivo sales were slower than expected. BMY stock gained. 
Via Investor's Business Daily
News headline image
Nasdaq Futures Climb As Meta, Amazon Gains Offset Apple Slide: Analyst Points to 2 Factors Reinforcing Bullish Outlook This Year ↗
Stock futures are pointing upwards on Friday as traders assess earnings reports from Meta Platforms, Inc. 
Via Benzinga
News headline image
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
From Bristol Myers Squibb
Via Business Wire
News headline image
Uncovering Dividend Opportunities with NYSE:BMY. ↗
Analyzing BRISTOL-MYERS SQUIBB CO (NYSE:BMY)'s Dividend Potential. 
Via Chartmill
News headline image
Earnings Scheduled For February 2, 2024 ↗
Companies Reporting Before The Bell • W.W. Grainger (NYSE:GWW) is likely to report quarterly earnings at $8.05 per share on revenue of $4.04 billion. 
Via Benzinga
News headline image
Investor Optimism Improves Following Earnings, Economic Reports; Dow Jumps Over 350 Points ↗
The CNN Money Fear and Greed index showed an increase in the overall market sentiment, but the index remained in the "Greed" zone on Thursday. 
Via Benzinga
Topics Stocks
News headline image
Amazon, Apple And 3 Stocks To Watch Heading Into Friday ↗
With U.S. stock futures trading mostly higher this morning on Friday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
News headline image
BMY Stock Dividend Delight: A Blue-Chip’s Healthy Yield ↗
In the grand theater of the financial markets, Bristol-Myers Squibb stands out as a robust performer. Despite the recent pullback, the market sentiment towards this biopharmaceutical titan remains... 
Via Talk Markets
News headline image
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60% ↗
Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions. 
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB), Exro Technologies Inc. (OTC – EXROF), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Did You Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts? ↗
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
News headline image
Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)
From Bristol Myers Squibb
Via Business Wire
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
Via Get News
News headline image
Bristol Myers' Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients ↗
Results from Bristol Myers Squibb's Phase 3 CheckMate -67T trial on subcutaneous Opdivo (nivolumab) for advanced clear cell renal cell carcinoma. Noninferiority compared to IV Opdivo. 
Via Benzinga
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
--News Direct-- 
Via News Direct
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
New York, Jan. 29, 2024 - (Plato Data) -- Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug... 
Via TheNewswire.com
News headline image
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism? ↗
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Subcutaneous Nivolumab (nivolumab and hyaluronidase) Shows Noninferiority Compared to Intravenous Opdivo (nivolumab) in Advanced or Metastatic Clear Cell Renal Cell Carcinoma in CheckMate -67T Trial
From Bristol Myers Squibb
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Karuna Therapeutics, Inc. (Nasdaq – KRTX), Carrols Restaurant Group, Inc. (Nasdaq - TAST), Ansys, Inc. (Nasdaq - ANSS), HomeStreet, Inc. (Nasdaq - HMST)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
3 Healthcare Stocks at 52-Week Lows: Buy or Bye? ↗
Investors should consider picking up these healthcare stocks at 52-week lows to benefit from their potential rebound. 
Via InvestorPlace
News headline image
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
News headline image
Gilead's Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of "Risks Of Secondary Cancer' ↗
FDA issues classwide black box warning for CAR-T therapies due to T-cell cancer risk. Drops Gilead's cell therapy from the list. 
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
82 83 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today